| A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes S Kashyap, R Belfort, A Gastaldelli, T Pratipanawatr, R Berria, ... Diabetes 52 (10), 2461-2474, 2003 | 712 | 2003 |
| Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients M Bajaj, S Suraamornkul, P Piper, LJ Hardies, L Glass, E Cersosimo, ... The journal of clinical endocrinology & metabolism 89 (1), 200-206, 2004 | 465 | 2004 |
| Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes AE Civitarese, CP Jenkinson, D Richardson, M Bajaj, K Cusi, S Kashyap, ... Diabetologia 47, 816-820, 2004 | 370 | 2004 |
| Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes M Bajaj, S Suraamornkul, T Pratipanawatr, LJ Hardies, W Pratipanawatr, ... Diabetes 52 (6), 1364-1370, 2003 | 337 | 2003 |
| SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes … Y Ye, M Bajaj, HC Yang, JR Perez-Polo, Y Birnbaum Cardiovascular drugs and therapy 31, 119-132, 2017 | 332 | 2017 |
| Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle DK Richardson, S Kashyap, M Bajaj, K Cusi, SJ Mandarino, J Finlayson, ... Journal of Biological Chemistry 280 (11), 10290-10297, 2005 | 294 | 2005 |
| Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients Y Miyazaki, A Mahankali, E Wajcberg, M Bajaj, LJ Mandarino, ... The Journal of Clinical Endocrinology & Metabolism 89 (9), 4312-4319, 2004 | 285 | 2004 |
| Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients M Bajaj, S Suraamornkul, LJ Hardies, T Pratipanawatr, RA DeFronzo International Journal of Obesity 28 (6), 783-789, 2004 | 227 | 2004 |
| Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients M Bajaj, S Suraamornkul, A Romanelli, GW Cline, LJ Mandarino, ... Diabetes 54 (11), 3148-3153, 2005 | 213 | 2005 |
| Metabolic and molecular basis of insulin resistance M Bajaj, RA DeFronzo Journal of nuclear cardiology 10 (3), 311-323, 2003 | 201 | 2003 |
| Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial C Abraira, W Duckworth, M McCarren, N Emanuele, D Arca, D Reda, ... Journal of Diabetes and its Complications 17 (6), 314-322, 2003 | 191 | 2003 |
| Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus M Bajaj, S Suraamornkul, LJ Hardies, L Glass, N Musi, RA DeFronzo Diabetologia 50, 1723-1731, 2007 | 174 | 2007 |
| The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial WC Duckworth, C Abraira, TE Moritz, SN Davis, N Emanuele, S Goldman, ... Journal of diabetes and its complications 25 (6), 355-361, 2011 | 172 | 2011 |
| Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects SR Kashyap, LJ Roman, J Lamont, BSS Masters, M Bajaj, ... The Journal of Clinical Endocrinology & Metabolism 90 (2), 1100-1105, 2005 | 163 | 2005 |
| Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type … M Bajaj, S Suraamornkul, S Kashyap, K Cusi, L Mandarino, RA DeFronzo The Journal of Clinical Endocrinology & Metabolism 89 (9), 4649-4655, 2004 | 140 | 2004 |
| Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes P Sathyanarayana, M Jogi, R Muthupillai, R Krishnamurthy, SL Samson, ... Obesity 19 (12), 2310-2315, 2011 | 135 | 2011 |
| Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial SL Samson, P Sathyanarayana, M Jogi, EV Gonzalez, A Gutierrez, ... Diabetologia 54, 3093-3100, 2011 | 133 | 2011 |
| Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes SR Kashyap, R Belfort, R Berria, S Suraamornkul, T Pratipranawatr, ... American Journal of Physiology-Endocrinology and Metabolism 287 (3), E537-E546, 2004 | 133 | 2004 |
| Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes K Cusi, S Kashyap, A Gastaldelli, M Bajaj, E Cersosimo American Journal of Physiology-Endocrinology and Metabolism 292 (6), E1775-E1781, 2007 | 131 | 2007 |
| Nicotine and insulin resistance: when the smoke clears M Bajaj Diabetes 61 (12), 3078, 2012 | 113 | 2012 |
